PDF(Pubmed)
Abstract：
UNASSIGNED: Discomfort has been related to the poor acceptance of a mandibular advancement device (MAD) in patients with obstructive sleep apnea. The present study compared severe initial side effects between a smaller and a larger degree of mandibular advancement in patients with a good protrusive capacity.
UNASSIGNED: Consecutive patients with obstructive sleep apnea and a good protrusive capacity (≥8 mm) were randomized to start treatment with the mandible advanced by either 70% of maximum protrusion (Adv70%) or by 4 mm (Adv4mm) in a pilot study with a parallel design. The main outcome was tenderness or pain in the teeth or jaws using a 0-10 visual analogue scale (VAS) (from \"not at all\" to \"very extensive\") or excluded use because of side effects during the first week of treatment. Secondary outcomes included salivation problems and bite changes.
UNASSIGNED: Eighteen patients were randomly selected and 17 patients fulfilled the study protocol. Four patients in the Adv70% group and none in the Adv4mm group reported severe tenderness or pain (VAS ≥7) on five or more of the seven days (p=0.03). The degree of mandibular advancement measured in millimeters correlated with the number of days with severe side effects, r=0.64 (p=0.006). The secondary side effects were minor.
UNASSIGNED: Starting MAD treatment with 70% mandibular advancement was related to more severe side effects during the first week of treatment compared with a smaller fixed millimeter value in patients with a good protrusive capacity in this pilot study.
UNASSIGNED: Consecutive patients with obstructive sleep apnea and a good protrusive capacity (≥8 mm) were randomized to start treatment with the mandible advanced by either 70% of maximum protrusion (Adv70%) or by 4 mm (Adv4mm) in a pilot study with a parallel design. The main outcome was tenderness or pain in the teeth or jaws using a 0-10 visual analogue scale (VAS) (from \"not at all\" to \"very extensive\") or excluded use because of side effects during the first week of treatment. Secondary outcomes included salivation problems and bite changes.
UNASSIGNED: Eighteen patients were randomly selected and 17 patients fulfilled the study protocol. Four patients in the Adv70% group and none in the Adv4mm group reported severe tenderness or pain (VAS ≥7) on five or more of the seven days (p=0.03). The degree of mandibular advancement measured in millimeters correlated with the number of days with severe side effects, r=0.64 (p=0.006). The secondary side effects were minor.
UNASSIGNED: Starting MAD treatment with 70% mandibular advancement was related to more severe side effects during the first week of treatment compared with a smaller fixed millimeter value in patients with a good protrusive capacity in this pilot study.
摘要：
■不适与阻塞性睡眠呼吸暂停患者对下颌前移装置（MAD）的接受度差有关。本研究比较了具有良好突出能力的患者下颌前移程度较小和较大的严重初始副作用。
■连续患有阻塞性睡眠呼吸暂停和良好的前伸能力（≥8mm）的患者被随机分配开始治疗，在平行设计的试验研究中，下颌骨前伸的70％（Adv70%）或4mm（Adv4mm）。主要结果是使用0-10视觉模拟评分（VAS）（从“根本没有”到“非常广泛”）或由于第一周的副作用而被排除使用的牙齿或颌骨的压痛或疼痛治疗。次要结果包括流涎问题和叮咬变化。
■随机选择18名患者，17名患者符合研究方案。在7天中的5天或更长时间，Adv70%组的4例患者和Adv4mm组中没有患者报告严重压痛或疼痛（VAS≥7）（p=0.03）。以毫米为单位测量的下颌前移程度与严重副作用的天数相关，r=0.64(p=0.006)。次要副作用较小。
■在本初步研究中，与具有良好突出能力的患者的较小固定毫米值相比，在治疗的第一周开始下颌前移率70％的MAD治疗与更严重的副作用有关。
■连续患有阻塞性睡眠呼吸暂停和良好的前伸能力（≥8mm）的患者被随机分配开始治疗，在平行设计的试验研究中，下颌骨前伸的70％（Adv70%）或4mm（Adv4mm）。主要结果是使用0-10视觉模拟评分（VAS）（从“根本没有”到“非常广泛”）或由于第一周的副作用而被排除使用的牙齿或颌骨的压痛或疼痛治疗。次要结果包括流涎问题和叮咬变化。
■随机选择18名患者，17名患者符合研究方案。在7天中的5天或更长时间，Adv70%组的4例患者和Adv4mm组中没有患者报告严重压痛或疼痛（VAS≥7）（p=0.03）。以毫米为单位测量的下颌前移程度与严重副作用的天数相关，r=0.64(p=0.006)。次要副作用较小。
■在本初步研究中，与具有良好突出能力的患者的较小固定毫米值相比，在治疗的第一周开始下颌前移率70％的MAD治疗与更严重的副作用有关。
